| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd7c27b9ec61781656e6f039702fd568 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 |
| filingDate |
2001-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b85f699c90dfae78e1b6a97b9ba0d677
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45eec9ea76d90a70658e166fddca87d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca4f12c0473039149da537cf5ad9a0ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_437d3a08b6508320c0953de050546912
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0311fc116e9981ad01555c4824bfaa0d |
| publicationDate |
2002-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0213790-A1 |
| titleOfInvention |
Solid dispersion of ipriflavone for oral administration and its manufacturing methods |
| abstract |
This invention relates to an ipriflavone-containing pharmaceutical agent for oral administration with improved bioavailability, wherein ipriflavone is solid-dispersed in the presence of a water-soluble polymer, an absorption fortifier, and an excipient while the crystal of said pharmaceutical agent is prepared in an amorphous form at the same time so that said ipriflavone can be enclosed in said water soluble polymer, and thus even a little amount as well as lower number of dosage of said ipriflavone pharmaceutical agent can increase the effective blood concentration of said ipriflavone pharmaceutical agent and the solubility for the body fluid in the gastrointestinal tract, thereby remarkably improving the bioavailability of said agent which can much reduce both the uncomfortableness in its usage and the burden that is usually laid on the gastrointestinal tract by a heavy dose and also increase the stability during a long-term storage. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009108077-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009108077-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8974823-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016009314-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-028259-B1 |
| priorityDate |
2000-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |